INTEGRATED BIOPHARMA INC INB Income Statement

Integrated biopharma inc (INB)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Dec'10	Sep'10
Sales, net
52,818	53,275	51,079	49,977	0	0	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales, net
-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of sales
45,961	46,177	44,677	43,755	42,850	39,961	39,042	38,722	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales, net
-	-	-	-	-	-	-	-	-	-	-	-	47,092	47,409	45,450	42,214	39,774	38,474	38,351	37,488	36,725	34,576	33,074	33,683	35,097	35,727	34,334	33,623	31,652	31,362	34,208	36,604	48,195	49,692	45,102	40,665	0	0	0
Cost of sales
-	-	-	-	-	-	-	-	-	-	-	-	40,242	40,573	39,109	36,710	35,222	34,347	33,944	33,095	32,180	30,203	28,487	28,800	29,744	29,864	28,801	28,122	26,693	26,296	27,789	28,997	35,269	36,049	33,145	30,503	0	0	0
Gross profit
6,857	7,098	6,402	6,222	6,108	5,484	5,202	4,988	5,228	5,098	5,520	6,667	6,851	6,836	6,341	5,504	4,552	4,127	4,407	4,393	4,545	4,373	4,587	4,883	5,353	5,863	5,533	5,501	4,959	5,066	6,419	7,607	12,926	13,643	11,957	10,162	0	0	0
Selling and administrative expenses
3,641	3,605	3,627	3,518	3,354	3,307	3,314	3,294	3,330	3,431	3,481	3,480	3,482	3,446	3,353	3,390	3,376	3,389	3,438	3,460	3,416	3,452	3,446	3,531	3,719	3,868	4,126	4,385	5,601	6,301	7,166	8,113	12,158	12,804	11,757	10,524	0	0	0
Operating income
3,216	3,493	2,775	2,704	2,754	2,177	1,888	1,694	1,898	1,667	2,039	3,187	3,369	3,390	2,988	2,114	1,176	738	969	933	1,129	921	1,141	1,352	1,634	1,995	1,407	1,116	-642	-1,235	-747	-506	768	839	200	-362	0	0	0
Other income (expense), net
Other income (expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	-	-	-
Interest expense
373	473	554	630	818	854	893	926	921	914	912	911	909	932	948	953	966	969	976	979	974	960	956	964	975	986	979	979	1,012	1,050	1,097	1,109	1,305	1,534	0	-	0	0	-
Forbearance fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-
Change in fair value of derivative liabilities
-	-	-	9	382	436	621	494	334	372	-177	-427	-577	-799	-429	-64	-124	47	488	705	662	631	266	-21	489	305	879	-133	-608	-435	-1,086	9	0	0	0	-	-	-	-
Realized gain on investment
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized gain on investment
0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment on investment in iBio Stock
-	-	-	-	-	-	-	358	287	287	119	36	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment charge on investment in iBio, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Other income, net
52	59	0	-	0	0	-	101	15	16	27	43	68	73	84	92	132	233	225	210	370	27	12	5	-353	0	0	-	0	-	-	-	-	-	-	37	0	0	0
Other income (expense), net
-335	-549	-598	-662	-423	-421	-446	-689	-859	-813	-1,181	-1,331	-1,418	-1,658	-1,293	-925	-958	-689	-263	-64	0	0	0	-	-	-944	14	-1,006	0	0	0	-	-2,329	-2,553	0	-	0	0	-
Income before income taxes
2,881	2,944	2,177	2,042	2,331	1,756	1,442	1,005	1,039	854	858	1,856	1,951	1,732	1,695	1,189	218	49	706	869	541	1,081	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Income before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,421	110	-2,256	-2,448	-4,035	-2,702	-1,466	-1,617	-1,493	-2,256	0	0	0
Provision for income taxes
314	390	336	354	185	145	425	326	-358	-393	-660	-490	394	380	329	231	116	86	133	134	78	81	75	89	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Income tax expense, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37	-58	0	-	0	0	-	-25	0	0	0
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
(Loss) income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Net income
2,567	2,554	1,841	1,688	2,146	1,611	1,017	679	1,397	1,247	1,518	2,346	1,557	1,352	1,366	958	102	-37	573	735	730	386	236	131	1,025	943	1,363	93	-2,240	-2,446	-4,048	-2,713	-2,141	-2,279	-1,917	-2,281	0	0	0
Change in fair value of derivative liability
-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0	-	-	-705	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liability
-	-	-	9	382	436	621	494	334	372	-177	-427	0	0	0	-	-	-	-	-	-	-	-	-	489	305	879	-133	-608	-435	-1,086	9	0	0	0	-	-	-	-
Interest expense, net of taxes
-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0	-	-	326	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of Convertible debt
-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0	-	-	110	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Diluted net income
-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	0	-	-	466	80	-264	-50	131	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense on Convertible debt-CD Financial, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Accretion of Convertible debt - CD Financial, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Diluted net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-
Diluted net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-
Continuing operations (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.03	-0.02
Discontinued operations (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01	0.02
Basic earnings per common share (in dollars per share)
0.03	0.03	0.01	0.01	0.03	0.01	0.01	0.04	0.02	-0.02	-0.01	0.07	0.01	0.00	0.03	0.04	0.00	0.00	0.01	-0.01	-0.01	0.03	0.02	0.00	-0.02	0.02	0.01	-	-0.03	0.04	-	-	-	-0.04	-	-	-	-0.02	0.00
Diluted earnings per common share (in dollars per share)
0.03	0.03	0.01	0.01	0.03	0.01	0.01	0.04	0.01	-0.02	-0.01	0.06	0.01	0.00	0.03	0.04	0.00	0.00	0.01	0.01	-0.01	0.01	0.01	0.01	-0.02	0.01	0.01	-0.03	-0.03	0.03	0.03	-	-0.04	-0.04	-	-	-	-	-
Weighted average common shares outstanding - basic (in shares)
29,565	29,565	29,565	29,545	29,565	29,392	27,218	21,135	21,135	21,135	21,135	21,131	21,125	21,106	21,105	21,105	21,105	21,105	21,105	21,105	21,105	21,105	21,105	21,087	21,080	21,080	21,080	-	21,080	21,080	-	-	-	20,986	-	-	-	-	-
Add: Equivalent shares outstanding (in shares)
1,319	1,025	1,158	830	542	506	744	-	836	-	0	-	1,434	-	77	116	176	0	50	0	0	0	199	208	76	73	89	-	-	-	-	-	-	-	-	-	-	-	-
Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in shares)
-	-	-	-	-	-	-	-	8,230	-	0	24,692	8,230	0	0	-	0	-	0	16,461	0	8,230	8,230	-	-	8,230	8,230	-	-	-	-	-	-	-	-	-	-	-	-
Add: Stock options (in Shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	219	-	-	-	-	-	-	-	-	-
Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in Shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,230	-	-	-	-	-	-	-	-	-
Basic and diluted net income (loss) per common share (in Dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.05	-	-	-	0.02	-	-0.04	-	-
Weighted average common shares outstanding - diluted (in shares)
30,885	30,590	30,724	30,375	30,108	29,898	27,963	48,796	30,202	21,135	21,135	47,614	30,791	21,106	21,182	21,221	21,281	21,105	21,155	37,566	21,105	29,335	29,535	4,910	21,080	29,383	29,400	13,283	21,080	29,530	21,080	21,085	21,036	20,986	20,936	-	20,786	20,797	20,625